References
- WHO. Cannabis. 2010 Dec 7. [cited 2017 Jan 29]. Available from: http://www.who.int/substance_abuse/facts/cannabis/en/
- Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes. 2006 Apr;30(Suppl 1):S13–S18.
- Zhang MW, Ho RC. The cannabis dilemma: a review of its associated risk and clinical efficacy. J Addict. 2015;2015:707596.
- Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry. 2015 Dec;72(12):1235–1242.
- Walsh Z, Callaway R, Belle-Isle L, et al. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Policy. 2013 Nov;24(6):511–516.
- Bonn-Miller MO, Boden MT, Bucossi MM, et al. Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. Am J Drug Alcohol Abuse. 2014 Jan;40(1):23–30.
- Mojtabai R, Olfson M. National trends in long-term use of antidepressant medications: results from the U.S. National Health and Nutrition Examination Survey. J Clin Psychiatry. 2014 Feb;75(2):169–177.
- Johansson T, Flamm M, Sönnichsen A, et al. Interventions to reduce inappropriate polypharmacy: implications for research and practice. Maturitas. 2017;97:66–68.
- Salvi F, Rossi L, Lattanzio F, et al. Is polypharmacy an independent risk factor for adverse outcomes after an emergency department visit? Intern Emerg Med [Internet]. 2016 Apr 13. DOI:10.1007/s11739-016-1451-5
- Isaac S, Saini B, Chaar BB. The role of medicinal cannabis in clinical therapy: pharmacists’ perspectives. PLoS One. 2016 May 12;11(5):e0155113.
- Rong C, Lee Y Carmona NE, et al. Cannabidiol in medical marijuana: research vistas and potential opportunities. Pharmacol Res. 2017;121:213–218.
- Dinis-Oliveira RJ. Metabolomics of Δ9-tetrahydrocannabinol: implications in toxicity. Drug Metab Rev. 2016 Feb 1;48(1):80–87.
- Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol. 1992 Sep;16(5):276–282.
- McGilveray IJ. Pharmacokinetics of cannabinoids. Pain Res Manage. 2005;10(Suppl a):15A–22A.
- Law B, Mason PA, Moffat AC, et al. Passive inhalation of cannabis smoke. J Pharm Pharmacol. 1984 Sep;36(9):578–581.
- Guengerich FP. Intersection of the roles of cytochrome P450 enzymes with xenobiotic and endogenous substrates: relevance to toxicity and drug interactions. Chem Res Toxicol. 2017 Jan 17;30(1):2–12.
- Matsunaga T, Iwawaki Y, Watanabe K, et al. Metabolism of delta 9-tetrahydrocannabinol by cytochrome P450 isozymes purified from hepatic microsomes of monkeys. Life Sci. 1995;56(23–24):2089–2095.
- Jiang R, Yamaori S, Takeda S, et al. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci. 2011 Aug 1;89(5–6):165–170.
- Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86–95.
- Wall ME, Sadler BM, Brine D, et al. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther. 1983 Sep;34(3):352–363.
- Anderson GD, Chan L-N. Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products. Clin Pharmacokinet. 2016 Nov;55(11):1353–1368.
- Gardner MJ, Tornatore KM, Jusko WJ, et al. Effects of tobacco smoking and oral contraceptive use on theophylline disposition. Br J Clin Pharmacol. 1983;16(3):271–280.
- Geffrey AL, Pollack SF, Bruno PL, et al. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015 Aug;56(8):1246–1251.
- Jiang R, Yamaori S, Okamoto Y, et al. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013 Jan 15;28(4):332–338.
- Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia. 1995;36(Suppl 5):S8–S13.
- Bajpai M, Roskos LK, Shen DD, et al. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos. 1996 Dec;24(12):1401–1403.
- Lindsey WT, Stewart D, Childress D. Drug interactions between common illicit drugs and prescription therapies. Am J Drug Alcohol Abuse. 2012 Jul;38(4):334–343.